Physician profile
Melvin Williams
NPI 1295762789
$2,303.21
in general payments reported to CMS, 2019-2025
15 companies · $181 in 2025
The $181 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $773 · 2020: $429 · 2021: $198 · 2022: $77.66 · 2023: $319 · 2024: $326 · 2025: $181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $826.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $825.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zyla Life Sciences, INC. | $644.48 | 2019-2020 | |
| Smith+Nephew, INC. | $473.01 | 2019-2021 | |
| Stryker Corporation | $318.72 | 2021-2025 | Citrefix, Actishield, Prostep Mica |
| Convatec INC. | $147.87 | 2024 | |
| Pfizer INC. | $143.23 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $137.95 | 2023-2024 | Xifaxan, Trulance |
| Biotissue Holdings INC. | $126.80 | 2023-2024 | |
| Assertio Therapeutics, INC. | $68.17 | 2019-2020 | |
| Averitas Pharma INC. | $54.61 | 2024 | Qutenza |
| Depuy Synthes Sales INC. | $47.50 | 2023 | Motoband, Na |
| Treace Medical Concepts, INC. | $45.05 | 2022-2025 | |
| Organogenesis INC. | $29.32 | 2022 | |
| Horizon Therapeutics Plc | $28.57 | 2019 | |
| Novo Nordisk INC | $20.44 | 2023 | |
| Kerecis Limited | $17.49 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melvin Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.